The Economics of NAMs: Promise, Costs, and the Challenges of Adoption
By CriShaun Hardy | October 29th, 2026
“As regulatory agencies increasingly recognize the potential of NAMs, evaluating their financial implications has become an important part of understanding whether and how these technologies can be integrated into existing research and regulatory systems.”
Release the Rabbits: What Two Decades of EU Skin Irritation Testing Trends Reveal About Replacing Animal Models
By Vesna Adjei | September 17th, 2026
“This has major implications for the United States as NAM-friendly legislation continues expanding through policies such as the FDA Modernization Act 2.0 and state-level cosmetic testing bans; Funding innovative methods is essential, but funding alone will not drive widespread replacement.”
Image by ALEXANDRE LALLEMAND
Snails, Snakes, and Sourcing Novel Compounds for Drug Development
By Anicca Harriot, PhD | September 3rd, 2026
“Holford’s new efforts to produce snail-based organoids could become a prominent tool in reducing and even replacing the use of live animals in production.”
Image by Marina Grynykha
Professional Perspectives: How Online NAM Platforms Are Changing Toxicity Testing
By Kinga Nimz, Karolina Jagiello, PhD and Maciej Stępnik, MD, PhD, DSc | August 20th, 2026
“By linking NAM knowledge platforms with computational tools and structured workflows, the field can move from isolated methods toward practical, decision-support systems for inhalation toxicity assessment.”
Image by Hans Reiner
How Legal Liability Concern is Slowing the Future of NAMs
By Mackensey Alexander | August 6th, 2026
“Without a robust regulatory acceptance pathway, legal liability concerns will continue to delay the widespread development and adoption of NAMs.“
Green Chemistry - The Prevention of Waste at the Source
By Shannon Dixon | July 23rd, 2026
“Ultimately, green chemistry shows that the most effective way to manage waste is to prevent it from being generated in the first place.“
The Replacement Trap: NAMs Are Built for Integration not One-for-One Animal Replacement
By Zachary Liebowitz | July 9th, 2026
“Right now, they're not yet ready to replace animal testing. That reality should not be seen as a limitation of the field, but as a reflection of where it is in its development and shows a need for more support. “
Reaching the goals of the AWA and HREA by reconsidering IACUC members and their roles
By Mariah Bowman | June 25th, 2026
“Although IACUCs do consider certain animal interests when evaluating research proposals (pain, housing, enrichment, etc.), there are other considerations not receiving the attention they deserve.”
More than a Guideline: Why Compliance with the PHS Policy is not Optional
By Akosua Dufie | June 11th, 2026
“For an animal research institution seeking federal dollars, compliance with the PHS Policy is not optional. Even though the PHS Policy is not enforced through punitive measures, it is still enforceable through the quiet but potent power of funding.”
What’s Next for the Second Species?
By Loza Taye | May 28th, 2026
“Last week, our team partnered with Cruelty Free International to host Examining the Second Species in ICH M3, a two-day workshop focused on current regulatory guidelines and emerging scientific approaches in drug development.”
Professional Perspectives: Refinement of Animal Toxicology Research Techniques: Ethical and Scientific Advantages of Microsampling
By Emily Zweig | May 21st, 2026
“As animal research is gradually replaced, conventional procedures can be refined to reduce the number of animals used and improve lab animal welfare—one such technique is microsampling.”
NAMs in Industry: FDA Shows Emerging Trends in Regulatory Submissions
By Jorge Gana | May 7th, 2026
“Commitments to open science, continued funding of NAM research, and first-hand participation in NAM development are all steps industry leaders can take to ensure that technology meets the demands for new and validated, nonclinical testing. ”
Professional Perspectives: Innovation Without Cruelty: Replacing Animals with Artificial Intelligence
By Anjali Kumar | April 23th, 2026
“There are challenges and limitations to consider before implementing AI to replace animal models; however, the potential of this new technology will vastly change how we view research and testing worldwide.”
Professional Perspectives: Adverse Outcome Pathways to Contextualize Mechanistic Data for Chemical and Radiation Research
By Vinita Chauhan | April 9th, 2026
“In this sense, applying AOPs should therefore be viewed as a methodological refinement rather than a paradigm shift. It offers a systematic way to assemble mechanistic information, identify data gaps, and communicate uncertainty more clearly.”
Xenotransplantation and the Future of Organ Supply: A Case for Human-Derived Alternatives
By CriShaun Hardy | March 26th, 2026
“Xenotransplantation is not the only scientific pathway being explored to address organ scarcity and perhaps should not be society’s first choice.””
Our Tiny Allies in Toxicological Testing Part 3 – Small Flowering Plants as Alternative Models
By Aaradhya Diwan | March 12th, 2026
“Should the scientific community seek to incorporate Arabidopsis thaliana more formally into a battery of tests for evaluating environmental toxicity, there would need to be increased effort to coordinate and standardize laboratory conditions across its use in toxicity studies.”
The Production of Antivenom and Implementing the 3Rs
By Mariah Bowman | February 26th, 2026
“This is why toxicovenomics is important – identifying the type of venom and the proteins involved helps produce antivenoms that are ethical, consistent with the 3Rs, and potentially more effective.”
SEC v. Jarkesy: What Does It Mean for Laboratory Animals?
By Blair Eagleson | February 12th, 2026
“Agencies such as the USDA should continue to use civil penalties through administrative proceedings unless future rulings explicitly curtail their authority to do so.”